Application note: Improved RP-HPLC to analyse intact mAb’s
Posted: 11 March 2021 | Merck | No comments yet
A fast, high-resolution, and reproducible reverse phase HPLC method using the BIOshell™ A400 Protein C4 column to analyse the intact mAb Trastuzumab.
This application note demonstrates that the BIOshell™ A400 Protein C4 column, based on a wide-pore (400 Å) Fused-Core® particle design, is ideally suited for separating the intact therapeutic monoclonal antibody (mAb) Trastuzumab. The retention time, area precision, quantification, and robustness make this RP-HPLC method ideal for biopharma QC. The method can also be used to monitor degraded product created by heat stress, making it suitable for stability studies.
Related content from this organisation
- MSD set to acquire novel antibody for B-cell malignancies
- Novel immunotherapy combination approved for endometrial cancer
- Innovating small molecule injectables: market forecast to 2033
- Ophthalmology acquisition to advance tri-specific antibody
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)
